Table 1.
Patient characteristics
| Characteristics | Training cohort (n = 335) | Validation cohort (n = 135) | P value |
|---|---|---|---|
| Median age at allo-HSCT, years (range) | 28 (1–66) | 31 (1–64) | 0.596 |
| Gender, n (%) | 0.635 | ||
| Male | 198 (59.1) | 83 (61.5) | |
| Female | 137 (40.9) | 52 (38.5) | |
| Underlying disease, n (%) | 0.704 | ||
| Acute myeloid leukemia | 187 (55.8) | 78 (57.8) | |
| Acute lymphoblastic leukemia | 143 (42.77) | 55 (40.7) | |
| Mixed-phenotype acute leukemia | 5 (1.55) | 2 (1.5) | |
| Disease status before allo-HSCT, n (%) | 0.535 | ||
| CR1 | 321 (95.8) | 131 (97.0) | |
| > CR1 | 14 (4.2) | 4 (3.0) | |
| Disease risk index before allo-HSCT, n (%) | 0.714 | ||
| Low and intermediate risk | 268 (80.0) | 110 (81.5) | |
| High and very high risk | 67 (20.0) | 25 (18.5) | |
| Donor/recipient relation, n (%) | 0.379 | ||
| Mother donor | 26 (7.8) | 12 (8.9) | |
| Collateral donor | 12 (3.6) | 0 (0.0) | |
| Others | 297 (88.7) | 123 (91.1) | |
| Donor/recipient gender matched, n (%) | 0.258 | ||
| Female donor/male recipient combination | 57 (17.0) | 29 (21.5) | |
| Others | 278 (83.0) | 106 (78.5) | |
| HCT-CI scores before allo-HSCT, n (%) | 0.121 | ||
| 0 (Low-risk) | 237 (70.7) | 105 (77.8) | |
| 1–2 (Intermediate-risk) | 74 (22.1) | 23 (17.0) | |
| ≥ 3 (High-risk) | 24 (7.2) | 7 (5.2) | |
| Median donor age at allo-HSCT, years (range) | 40 (9–70) | 36 (10–63) | 0.094 |
| Cytomegalovirus serostatus before HSCT, n (%) | 0.501 | ||
| Donor +/recipient + | 312 (93.1) | 128 (94.8) | |
| Donor +/recipient − | 11 (3.3) | 3 (2.2) | |
| Donor −/recipient + | 10 (3.0) | 4 (3.0) | |
| Donor −/recipient − | 2 (0.6) | 0 (0.0) | |
| Number of HLA-A, HLA-B, HLA-DR mismatches, n (%) | 0.914 | ||
| 1 Locu | 8 (2.4) | 3 (2.2) | |
| ≥ 2 Loci | 327 (97.6) | 132 (97.8) | |
| Blood group compatibility, n (%) | 0.719 | ||
| Matched | 175 (52.2) | 73 (54.1) | |
| Mismatched | 160 (47.8) | 62 (45.9) | |
| Conditioning regimen, n (%) | 0.350 | ||
| Chemotherapy-based regimen | 325 (97.0) | 133 (98.5) | |
| TBI-based regimen | 10 (3.0) | 2 (1.5) | |
| Cell type, median count (range) | |||
| MNC counts (× 108/kg) | 9.2 (4.4–27.3) | 9.3 (4.2–27.5) | 0.218 |
| CD34+ cell counts (× 106/kg) | 3.8 (0.7–25.33) | 3.9 (1.1–29.4) | 0.572 |
| CD3+ cell counts (× 106 kg) | 340.9 (116.2–874.2) | 352.0 (170.4–1172.2) | 0.617 |
| CD4+ cell counts (× 106/kg) | 182.5 (68.3–600.1) | 184.7 (75.2–492.7) | 0.688 |
| CD8+ cell counts (× 106/kg) | 126.7 (29.6–347.9) | 128.0 (46.1–1511.2) | 0.559 |
| CD14+ cell counts (× 106/kg) | 211.3 (73.3–1065.0) | 215.6 (95.8–716.9) | 0.373 |
| CD8+/CD3+ cells ratio | 0.4 (0.2–0.7) | 0.4 (0.1–1.3) | 0.817 |
| CD4+/CD8+ cells ratio | 1.5 (0.4–4.7) | 1.5 (0.3–3.0) | 0.672 |
| CD4+/CD3+ cells ratio | 0.6 (0.2–0.8) | 0.5 (0.1–0.7) | 0.627 |
| CD3+/CD14+ cells ratio | 1.6 (0.6–4.4) | 1.5 (0.6–3.7) | 0.601 |
| Median follow-up of survivors, days (range) | 203 (62–490) | 192 (52–509) | 0.134 |
allo-HSCT, allogeneic hematopoietic stem cell transplantation; CR, complete remission; HLA, human leukocyte antigen; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; MNC, mononuclear cells; TBI, total body irradiation